Definitive Contract 75N91022C00053
Award Date 9/19/22
Potential Completion Date 9/18/24
Potential Value $2M
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Albany, CA 94710, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
3
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- This SBIR Phase I contract from the National Institutes of Health's National Cancer Institute was awarded to Indee Inc., doing business as Indee Inc., located in Albany, California. The firm fixed price contract valued at $399,299 will support research and development of microfluidic vortex shedding as a low-cost, high-efficiency method for genetic modification to support cell engineering for cell-based immunotherapies. The contract was awarded under a total small business set-aside solicitation...
- <p>This is a $299,999.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Innogenomics Technologies, L.L.C., a minority-owned small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract is for research and development in the area of biomedical (basic research). It was awarded on September 22, 2015 with a final completion date of March 21, 2017. The contract has a total small business set-aside designation.</p>
- This is a $189,094.00 Firm Fixed Price contract awarded by the National Cancer Institute, a civilian agency, to Angiocrine Bioscience, Inc., a for-profit organization. The contract is for the "SBIR PHASE I LARGE SCALE PROPAGATION OF CANCER CELLS USING THE VERAVEC PLATFORM IN AN AUTOMATED CLOSED SYSTEM" and was set aside for small businesses. The contract has an ultimate completion date of July 21, 2016 and was awarded on September 22, 2015. This appears to be a Small Business...
- <p>This SBIR Phase I contract was awarded by the National Cancer Institute (NCI), a civilian federal agency, to Transgenex Nanobiotech Inc., a minority-owned small business, for the development of a "fibrous scaffold-induced spheroids mimicking TME" solution. The contract, valued at $299,992.00, is a definitive, firm fixed-price contract with a completion date of July 21, 2014. The contract was set aside for the participation of small businesses.</p>
- This SBIR Phase I contract was awarded by the National Institutes of Health's National Cancer Institute to Cellfe Inc. for $358,930. The contract is for the period of September 8, 2020 through June 7, 2021 and involves research and development of a microfluidic transfection platform for rapid manufacturing of mRNA CAR lymphocyte products. The solicitation sought proposals to conduct R&D in support of NIH and CDC agency missions, including alternatives to cell culture materials and cancer...
- This is a $355,000.00 Firm Fixed Price definitive contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to Immunotarget Therapeutics Inc., a woman-owned small business. The contract is for the NCI's Small Business Innovation Research (SBIR) Innovative Concept Award program, which seeks proposals for highly innovative therapies, diagnostic tools, or preventive strategies focused on pediatric and/or rare cancers. The...
- This is a $355,000.00 Firm Fixed Price contract awarded by the National Institutes of Health (NIH) National Cancer Institute (NCI) to Petri Bio Inc., a small business, under the Small Business Innovation Research (SBIR) Phase I program. The contract is for the development of engineered microbial therapeutics for the treatment of heritable forms of glioma, a type of brain cancer. The work is focused on demonstrating technical feasibility and proof-of-concept for this therapeutic technology....
- <p>This is a federal contract awarded by the National Cancer Institute, a civilian agency, to Transgenex Nanobiotech Inc., a minority-owned small business. The contract, valued at $224,999.00, is for a Small Business Innovation Research (SBIR) Program Phase I action. The contract is a definitive, firm-fixed-price contract with a completion date of September 15, 2015. This contract is set aside for small businesses.</p>
- This definitive contract from the National Institutes of Health's National Cancer Institute, valued at $398,001, was awarded to Ferrologix Inc. to address Topic 397 under a Small Business Innovation Research Program Phase I solicitation. Specifically, the prime contractor will conduct research and development to functionally close the purification and elution of untouched T cells using cleavable magnetic beads with ratcheting cytometry. This firm fixed price contract has a period of...
- This is a $2,049,979 Firm Fixed Price Definitive Contract awarded by the National Cancer Institute (NCI), a civilian agency, to Proteios Technology, Inc., a self-certified small disadvantaged business. The contract is for SBIR Phase II research and development to support a "New Paradigm for Autologous and Allogeneic Cell Therapy Manufacturing" over a two-year period. This contract was set aside for total small business participation and is related to an earlier $455,000 SBIR Phase I...